Press Releases

<<  Back

  View printer-friendly version

Aimmune Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference

— Presentation on Thursday, January 14, 2016, at 11:00 a.m. Pacific Time

BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 6, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 14, 2016, at 11:00 a.m. Pacific Time.

A live audio webcast of the presentation will be accessible from the Investor Relations section of the Aimmune website at www.aimmune.com. A replay of the webcast will be available at www.aimmune.com for 14 days following the event.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for peanut allergy and other food allergies. The company’s characterized oral desensitization immunotherapy (CODIT™) system, an approach to oral immunotherapy (OIT), uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to obtain clinically meaningful desensitization to food allergens. Aimmune Therapeutics plans to initiate enrollment in a Phase 3 study of its lead product, AR101, a complex mixture of natural peanut proteins and pharmaceutical-grade ingredients for the treatment of peanut allergy, one of the most common food allergies, at the beginning of 2016. AR101 has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age. For more information, please see www.aimmune.com.

Source: Aimmune Therapeutics, Inc.

Investors
Stern Investor Relations
Beth DelGiacco, 212-362-1200
beth@sternir.com
or
Media
Edelman
Amanda Breeding, 415-229-7649
amanda.breeding@edelman.com